Bigfoot Unity connected pen-cap system
Bigfoot Biomedical (Abbott)
What it is
An FDA-cleared US prescription system with active support information for existing users. It replaces the caps on rapid- and long-acting disposable pens; the rapid cap scans Libre 2 and displays clinician-programmed guidance. The current manufacturer site does not provide a public new-start ordering or enrolment pathway, so broad new-start retail access is unverified.
Editorial review: .
Most recent recorded citation date: 2025-06-20. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Dose guidance: The rapid cap shows clinician-programmed meal and correction suggestions using current glucose, trends, and recent insulin; it withholds correction advice when rapid insulin may still be active.[2]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 62 × 18 + 82 × 20 + 65 × 15 + 25 × 12 + 45 × 15 + 30 × 10 + 25 × 10 = 5256; divide by total weight 100. Unrounded weighted result: 52.56.
Both caps track dose timing when replaced on the pen, reducing forgotten injections, but the workflow is less complete than a pen that transmits exact dialed units automatically.[1]
The rapid cap shows clinician-programmed meal and correction suggestions using current glucose, trends, and recent insulin; it withholds correction advice when rapid insulin may still be active.[2]
The white cap reads Libre 2 glucose and trend data directly, but requires an active scan at least every eight hours and does not support newer Libre or Dexcom sensors.[2]
Advice appears on the pen cap, but two rechargeable caps, cap-specific pen fit, and eight-hour Libre scans create more upkeep than an integrated pen.[2]
Multiple disposable insulin pens are supported through model-specific caps, but glucose integration is Libre 2 only and the system must not be used to control an AID system.[1]
FDA-cleared and still supported for US users, with coverage varying by plan. The current manufacturer pages document product use and support but provide no public ordering or enrolment pathway; broad access for new starts is therefore unverified.[2]
These tools do not automate basal insulin. Scores reflect what the shipping product does for injection users: reliably capturing doses, turning glucose and insulin-on-board data into useful guidance, and reducing daily burden without hiding regional or insulin-cartridge lock-in.
The full picture
Bigfoot Unity puts glucose and dose advice on the insulin pen itself. A white cap replaces the cap on a compatible rapid-acting disposable pen; scanning its paired FreeStyle Libre 2 sensor shows glucose, trend, a clinician-programmed meal dose, and—when appropriate—a correction dose. A black cap for long-acting insulin shows the prescribed dose and time since the last injection.21
The trade-off is lock-in and upkeep. It uses Libre 2 only, requires a scan at least every eight hours to avoid data gaps, and a change of insulin pen may require a different cap. Both caps recharge by cable. It is not for half-unit dosing, more-than-once-daily long-acting insulin, pregnancy, dialysis, or people under 12 under its FDA labeling.1
Access needs a narrower claim. FDA clearance and a live customer-support site show that the system exists and that current users can obtain help. They do not prove that a new patient can order it today: Bigfoot's current pages provide no public new-start ordering, clinic-enrolment, or retail-pharmacy pathway. As of 8 August 2026, broad US access for new starts is therefore unverified, not assumed from the older clearance and launch materials.2
There is also an open, narrow Class II recall worth separating from the whole product. In May 2025 Bigfoot recalled 57 identified caps running firmware 1.3.0 because a device error could make them unresponsive and remove information needed for a timely dosing decision. FDA recall Z-1997-2025 remained open when rechecked on 8 August 2026; this does not mean every Bigfoot Unity cap is recalled.3
Sources
- [1]FDA 510(k) decision summary K202145 — Bigfoot Unity · Regulatory decision · 2021-05-10
U.S. FDA. 510(k) decision summary K202145 — Bigfoot Unity Diabetes Management System.
- [2]Bigfoot Unity customer FAQ and current support information · Manufacturer — Current instructions and customer-care details establish support for people using the system. The page does not provide a new-start ordering or enrolment route, so it cannot by itself establish broad retail access.
Bigfoot Biomedical. Bigfoot Unity customer FAQs.
- [3]FDA Class II recall Z-1997-2025 — Bigfoot Unity firmware 1.3.0 caps · Regulatory decision · 2025-06-20 — Open as of 8 August 2026; 57 specific caps were recalled because a device error could leave the cap unresponsive. This is not a recall of every Bigfoot Unity cap.
U.S. FDA. Class II Device Recall Bigfoot Unity Diabetes Management System, Z-1997-2025.